Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 120, Issue 9, Pages 896-902
Publisher
Springer Science and Business Media LLC
Online
2019-04-04
DOI
10.1038/s41416-019-0443-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
- (2018) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Current progress in immunotherapy of hepatocellular carcinoma
- (2017) Martin F. Sprinzl et al. JOURNAL OF HEPATOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
- (2017) Abhishek D. Garg et al. OncoImmunology
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
- (2016) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons
- (2015) Antoine Hollebecque et al. EUROPEAN JOURNAL OF CANCER
- First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study
- (2015) Ying Liu et al. International Journal of Clinical Oncology
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study
- (2014) S. Qin et al. ONCOLOGIST
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) C. Verslype et al. ANNALS OF ONCOLOGY
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
- (2012) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study
- (2012) Aziz Zaanan et al. JOURNAL OF HEPATOLOGY
- High hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study
- (2012) Jin-Yong Zhou et al. Virology Journal
- Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma
- (2010) Ghassan K. Abou-Alfa et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting
- (2010) Caroline Tournoux-Facon et al. JOURNAL OF HEPATOLOGY
- Phase II Study of Oxaliplatin in Patients With Unresectable, Metastatic, or Recurrent Hepatocellular Cancer
- (2009) Y Yen et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma
- (2008) Amani Asnacios et al. CANCER
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now